Industry News
Prozac prevents onset of Huntington's disease in mice
A collaborative study by Australian and UK neuroscientists has shown that the anti-depressant fluoxetine (Prozac) prevents the onset of Huntington's disease (HD) in transgenic HD mice. [ + ]
Funding for medical research and Thank You Day campaign launch
The latest commonwealth government funding announcement for health and medical research will see AUD$292 million allocated to more than 600 projects across 52 Australian universities, hospitals and medical research institutes. [ + ]
Peplin obtains positive anti-leukemia results for drug candidate in mouse model
Peplin (ASX:PEP) has produced positive results from an initial efficacy study of its drug candidate PEP005 IV in a mouse model of acute myeloid leukemia. [ + ]
Single cell research
Using a water droplet 1 trillion times smaller than a litre of soda as a sort of nanoscale test tube, a University of Washington scientist is conducting chemical analysis and experimentation at unprecedented tiny scales.
[ + ]Avantogen signs license agreement with Hawaii Biotech
Avantogen (ASX:ACU), formerly Australian Cancer Technology, has signed a worldwide, nonexclusive license agreement with Hawaii Biotech to evaluate Avantogen's proprietary adjuvant GPI-0100 with a series of vaccines. [ + ]
Anadis to sell Travelan in USA
Melbourne biopharmaceutical company Anadis (ASX:ANX) has received legal advice that its over-the-counter traveller's diarrhoea product, Travelan, complies with all US federal and state regulations for sale in the dietary and medical foods categories. [ + ]
Researchers address the meaning of the genomic revolution
Genetics genomics have disturbed science's dreams of explaining human nature and individuality as merely a function of the activity of genes, modulated by environmental factors, according to University of Queensland Federation Fellow Professor Paul Griffiths. [ + ]
AtCor Medical to list on ASX in November
Sydney-based devices company AtCor Medical has lodged its prospectus for an initial public offering (IPO) to raise AUD$15 million for expanding the US marketing and sales of its cardiovascular diagnostic device, SphygmoCor. [ + ]
A wee step forward
Physicists in Singapore have created the first paper battery that generates electricity from urine.
[ + ]Starpharma secures full ownership of VivaGel technology
Melbourne drug developer Starpharma (ASX:SPL) has acquired outright ownership of its VivaGel technology following changes to licence arrangements that were executed when Starpharma was spun-out of the Biomolecular Research Institute (BRI) in 1996. [ + ]
Solbec's managing director resigns
Perth-based Solbec Pharmaceuticals' (ASX:SBP ) managing director, Stephen Carter, has resigned. [ + ]
Money flows back into Australian biotech stocks: Intersuisse
Cash is finally flowing towards biotechnology and medical device stocks after a long and sustained drought, according to Intersuisse biotechnology index for the quarter ended September 2005. [ + ]
Avantogen cancer gene test partnership progressing
A partnership initiated in 2003 between Avantogen (ASX:ACU) (formerly Australian Cancer Technology) and Prof Ursula Kees at Perth's Telethon Institute for Child Health Research is closer to developing a diagnostic test to enable more effective treatment of cancer. [ + ]
SciGen signs US$145m hep B distribution deal
Singapore-based generics company SciGen (ASX:SIE) has signed a Chinese distribution agreement worth at least US$145 million (AUD$191.6 million) with Hefei Life Science Park Investment & Development (HID) for its hepatitis B product, Sci-B-Vac. [ + ]
Medical Developments International appoints new CEO
Melbourne-based Medical Developments International (ASX:MVP, MDI) has appointed Dr Simon Fisher as its new CEO, starting today. [ + ]
